ScreenerHero

BHC Bausch Health Companies Inc.

NYSE · US · Healthcare · Drug Manufacturers - Specialty & Generic · bauschhealth.com
6.150USD+2.16%Mkt Cap: 2.30B $P/E: —

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The comp…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap2.30B USD
Enterprise Value22.17B USD
Revenue (TTM)10.85B USD
Gross Profit7.25B USD
Net Income (TTM)157.00M USD
Revenue/Share29.12 USD
Last Price6.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20.3K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.44
PEG0.01
EV/EBITDA5.67
EV/Revenue2.04
P/S0.21
P/B-1.27
EPS (TTM)-2.95
EPS (Forward)4.19
52W Range
4.33050% of range8.000
52W High8.000 USD
52W Low4.330 USD
Profitability
Gross Margin70.65%
Oper. Margin27.17%
EBITDA Margin36.01%
Profit Margin1.53%
ROE-28.34%
ROA0.60%
Growth
Revenue Growth12.70%
Earnings Growth70.40%
Cash Flow & Leverage
Operating CF1.40B USD
CapEx (TTM)407.00M USD
FCF Margin13.21%
FCF Yield62.33%
Net Debt18.95B USD
Net Debt/EBITDA4.85
Balance Sheet
Debt/Equity-37.64
Current Ratio1.44
Quick Ratio0.90
Book Value/Sh-4.74 USD
Cash/Share4.88 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield1.30%
Payout Ratio0.00%
Ex-Div DateNov 10, 2010
Pay Date—
Splits
Last Split2:1
Split DateOct 16, 2000
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.500 USD
Upside (mean)+22.0%
Target Range6.500 USD – 9.000 USD
6.500+22.0% to mean9.000
# Analysts5
Ownership
Shares Out.373.99M
Float260.57M
Insiders11.12%
Institutions65.07%
Short Interest
Short Ratio3.1d
Short % Float2.88%
Short % Out.2.31%
Shares Short8.63M
Short (prev mo.)8.42M
Technical
SMA 506.115 (+0.6%)
SMA 2005.773 (+6.5%)
Beta0.37
S&P 52W Chg15.78%
Avg Vol (30d)2.20M
Avg Vol (10d)1.75M
Technical Indicators
RSI (14)57.7
MACD-0.0396
MACD Signal-0.0867
MACD Hist.+0.0471
BB Upper6.096 USD
BB Middle5.801 USD
BB Lower5.506 USD
BB Width10.17%
ATR (14)0.2490 USD
Vol Ratio (20d)0.98x